An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N[t]RTIs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in the Rilpivirine Pediatric Studies

Trial Profile

An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N[t]RTIs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in the Rilpivirine Pediatric Studies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 28 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 15 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top